Clinical meaningfulness of Alzheimer's Disease Assessment Scale–Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction: The clinical meaningfulness of Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS‐Cog) subscale change is disputed. We compared 2‐ to 4‐point ADAS‐Cog changes with changes in Goal Attainment Scaling (GAS) and everyday function across initial ADAS‐Cog scores and treatment responses. Methods: This exploratory analysis evaluated mild‐moderate Alzheimer's disease patients treated with donepezil (12 months) or galantamine (8 months). Clinical meaningfulness was defined as concomitant ADAS‐Cog and GAS changes of ±3 points and/or functional improvement. Results: Patients with ≥3‐point ADAS‐Cog improvement significantly improved on GAS but not on standard tests of everyday function. ADAS‐Cog “no change” (≤±3 points) was seen with mean GAS improvement. Initial ADAS‐Cog improvement made endpoint improvement (ADAS‐Cog 3 points and GAS 1 point) more likely (odds ratio = 6.9; 95% confidence interval = 2.5–19.5). In contrast, initial deterioration made endpoint improvement unlikely (0.33; 0.14–0.64). Discussion: ADAS‐Cog improvement and no change were each associated with GAS improvement. Initial ADAS‐Cog worsening was unlikely to result in later improvement. Clinical trial registration number: ISRCTN26167328.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 5×
“In contrast, ADAS-Cog deterioration would have been fully captured by the DAD.”
MethodInfluentialA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Raghavan, N., Samtani, M. N., Farnum, M., Yang, E., Novak, G., Grundman, M., Narayan, V., DiBernardo, A., & Initiative, A. D. N. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2187 · Cited by 96 · cited 1×
“It remains widely used, despite concerns about its psychometric properties [5–7], especially in the early stages of dementia [8,9].”
BackgroundKurz, A. F., Leucht, S., & Lautenschlager, N. T. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211001001 · Cited by 82 · cited 3×
“Although, as here, the correspondencewith cognitive test scores is not always exact [36], statistically significant treatment effects in double-blinded clinical trials powerfully suggest clinicallymeaningful benefits [33].”
Background
Cited by
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
Joe, E., & Ringman, J. M. (2019) · BMJ · doi:10.1136/bmj.l6217 · Cited by 321
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citationBuilding clinically relevant outcomes across the Alzheimer's disease spectrum
Rentz, D. M., Wessels, A. M., Annapragada, A. V., Berger, A., Edgar, C. J., Gold, M., Miller, D. S., Randolph, C., Ryan, J. M., Wunderlich, G., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12181 · Cited by 38
Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment.
Lim, A. W. Y., Schneider, L., & Loy, C. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub4 · Cited by 24
Metadata
- Authors
- Rockwood, K., Howlett, S. E., Hoffman, D., Schindler, R., & Mitnitski, A.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-03-21
- Volume
- 13
- Issue
- 10
- Pages
- 1098-1106
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2603394656
- Cited by
- 29
- References
- 6
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.